Quantum-Si (QSI) AI Stock Analysis

• Market Cap: $441.44M
• Dividend Yield: N/A
• Average Volume (3M): 18.26M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.63
• Revenue Growth: 100.47%
• EPS Growth: -5.71%
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.16
• Shares Outstanding: 182,557,700
• 10 Day Avg. Volume: 23,763,178
• 30 Day Avg. Volume: 18,264,308
• PEG Ratio: -0.87
• Price to Book (P/B): 1.79
• Price to Sales (P/S): 126.43
• P/FCF Ratio: -4.19
• Enterprise Value/Market Cap: 0.36
• Enterprise Value/Revenue: 45.97
• Enterprise Value/Gross Profit: 86.46
• Enterprise Value/Ebitda: -1.47
• 1Y Price Target: $3.15
• Price Target Upside: 34.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 55 Neutral
• Price Target: $2.50 ▲(6.84% Upside)

Quantum-Si's overall stock score reflects significant financial challenges, despite positive technical indicators. The company's strong cash position and strategic initiatives in product development offer potential for future growth, but current valuation concerns and financial performance weigh heavily on the score.

Positive Factors

Innovation and Product Development

Quantum-Si's progress on its innovation roadmap, including the upcoming launch of its version 4 sequencing kit, reflects strong R&D capabilities and positions the company for future growth in the proteomics market.

Strong Cash Position

A robust cash position provides Quantum-Si with the financial flexibility to invest in strategic initiatives, sustain operations, and navigate market uncertainties, supporting long-term business stability.

Expansion in Pharma and Biotech Opportunities

The significant increase in opportunities within the pharma and biotech sectors indicates strong market demand and potential for revenue growth, enhancing Quantum-Si's market position.

Negative Factors

Consistent Financial Losses

Ongoing financial losses and negative cash flows pose risks to Quantum-Si's financial health, potentially limiting its ability to invest in growth initiatives and affecting long-term sustainability.

Revenue Impact from NIH Funding Uncertainty

The uncertainty in NIH funding impacts Quantum-Si's revenue, particularly affecting capital sales in the U.S. academic market, which could hinder growth in a key customer segment.

Increased Operating Expenses

Rising operating expenses, including costs related to litigation settlements, could pressure Quantum-Si's profitability and cash flow, challenging its ability to achieve financial stability.

Quantum-Si Business Overview & Revenue Model

Company Description

Quantum-Si (QSI) is a biotechnology company focused on advancing the field of proteomics through its proprietary next-generation protein sequencing technology. Operating primarily in the life sciences sector, Quantum-Si aims to unlock the potential of proteins to drive discoveries in drug development, diagnostics, and personalized medicine. The company's core product offerings include its protein sequencing platform and related software solutions, which enable researchers and clinicians to analyze protein structures and functions with unprecedented accuracy and speed.

How the Company Makes Money

Quantum-Si generates revenue through multiple streams including the sale of its protein sequencing systems and reagents, as well as software licenses for its analytical tools. The company targets academic and commercial research institutions, pharmaceutical companies, and biotechnology firms that require advanced proteomic analysis capabilities. Significant partnerships with academic institutions and research organizations help to enhance its product development and validate its technology, potentially leading to further revenue opportunities. Additionally, QSI may explore collaborations for joint research projects or co-development agreements that can contribute to its earnings.

Quantum-Si Financial Statement Overview

Summary

Quantum-Si is facing significant financial challenges with consistent losses and negative cash flows. While the company maintains a low debt level, its inability to generate positive returns and cash flows poses risks to its financial health. Strategic improvements are necessary to enhance profitability and cash generation.

Income Statement

Quantum-Si shows a challenging financial position with negative net profit margins and declining revenue growth. The gross profit margin is positive, indicating some efficiency in production, but the company struggles with high operating losses as reflected in negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet reflects a low debt-to-equity ratio, suggesting conservative leverage. However, the negative return on equity indicates that the company is not generating profits from its equity base, which is a concern for long-term sustainability.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, which are concerning. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is somewhat aligned with reported losses, but the overall cash flow position is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.41M	3.06M	1.08M	0.00	0.00	0.00
Gross Profit	1.81M	1.60M	488.00K	-2.58M	-1.04M	-894.00K
EBITDA	-106.38M	-103.98M	-91.80M	-129.86M	-95.87M	-35.80M
Net Income	-106.46M	-101.01M	-95.96M	-141.04M	-88.95M	-36.61M
Balance Sheet
Total Assets	254.41M	247.87M	298.25M	391.49M	503.23M	40.59M
Cash, Cash Equivalents and Short-Term Investments	214.21M	209.60M	257.74M	351.31M	471.30M	36.91M
Total Debt	11.14M	12.95M	15.30M	17.45M	8.08M	1.75M
Total Liabilities	33.42M	32.45M	26.63M	32.78M	26.19M	4.50M
Stockholders Equity	220.98M	215.42M	271.62M	358.71M	477.03M	36.09M
Cash Flow
Free Cash Flow	-96.37M	-92.38M	-99.31M	-101.30M	-72.58M	-33.03M
Operating Cash Flow	-92.39M	-87.80M	-94.04M	-90.56M	-66.81M	-32.57M
Investing Cash Flow	-29.19M	-32.67M	143.43M	137.19M	-450.94M	-461.00K
Financing Cash Flow	84.21M	35.88M	149.00K	1.91M	516.63M	37.01M

Quantum-Si Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.34
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QSI, the sentiment is Positive. The current price of 2.34 is above the 20-day moving average (MA) of 2.06, above the 50-day MA of 1.58, and above the 200-day MA of 1.60, indicating a bullish trend. The MACD of 0.21 indicates Positive momentum. The RSI at 55.96 is Neutral, neither overbought nor oversold. The STOCH value of 25.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QSI.

Quantum-Si Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QSI	―	$441.44M	―	-46.87%	―	100.47%	-5.71%
SEER	―	$128.87M	-1.67	-25.25%	―	12.13%	-8.23%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DSGN	―	$326.31M	-5.12	-26.77%	―	―	-24.60%
FHTX	―	$230.08M	-3.28	―	―	-31.30%	36.26%
TNYA	―	$270.54M	-1.73	-85.21%	―	―	38.94%
ERAS	―	$675.13M	―	-31.16%	―	―	50.77%

Quantum-Si Corporate Events

Quantum-Si Enters Sales Agreement with Leerink Partners

On September 26, 2025, Quantum-Si Incorporated entered into a Sales Agreement with Leerink Partners LLC to potentially offer and sell up to $100 million of its Class A common stock. The agreement allows for sales at the company’s discretion and is contingent upon the effectiveness of a shelf registration statement filed with the SEC. The arrangement provides flexibility in stock sales, with Leerink Partners acting as sales agent, and includes provisions for commissions and legal expense reimbursements. This strategic move could impact Quantum-Si’s market presence and financial strategy, although the company is not obligated to sell any shares.

The most recent analyst rating on (QSI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Quantum-Si stock, see the QSI Stock Forecast page.

Quantum-Si Terminates Lease Agreement with Winchester Office

Quantum-Si Incorporated and Winchester Office LLC have agreed to terminate their lease agreement for premises in New Haven, CT, originally set to expire in 2032. As part of the settlement, Quantum-Si will pay a termination fee of $11 million, adjusted for credits, and will have no further rent obligations after September 23, 2025.

The most recent analyst rating on (QSI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Quantum-Si stock, see the QSI Stock Forecast page.

Quantum-Si Updates Corporate Presentation on Growth

On August 8, 2025, Quantum-Si Incorporated updated its corporate presentation, highlighting its strategic positioning and growth in the proteomics market. The company reported a 33% year-over-year growth in its user base for the first half of 2025 and announced the introduction of multiple instrument acquisition options. With a well-capitalized position and a cash runway into Q2 2028, Quantum-Si is poised to expand its market presence further. The company’s Proteus platform, expected to launch in the second half of 2026, is designed to address a broad range of proteomics analysis methods, potentially enhancing its competitive edge in the industry.

The most recent analyst rating on (QSI) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Quantum-Si stock, see the QSI Stock Forecast page.

Quantum-Si Q2 2025 Earnings Call Highlights Resilience

Quantum-Si Incorporated’s recent earnings call painted a picture of resilience and strategic adaptation amidst external challenges. The company emphasized its significant progress in technology development and strategic initiatives aimed at addressing market uncertainties. Despite revenue setbacks due to external factors, Quantum-Si is implementing new strategies to maintain its financial strength. The advancements in product offerings and a robust cash position contribute to a positive outlook for the company.

Quantum-Si Reports Growth and Strategic Developments

Quantum-Si Incorporated, a leader in proteomics technology, is revolutionizing protein analysis with its single-molecule detection platform. The company recently announced its second quarter 2025 financial results, highlighting significant developments in product offerings and financial performance.